AR and prostate carcinoma: We first examined the effects of InuA on the growth of three prostate cancer cell lines harboring different p53 and AR backgrounds, including LNCaP (p53 wild type, AR positive), PC3 (p53 null, AR negative) and DU145 (p53 mutant, AR negative) cells, and a normal fibroblast cell line (IMR90).